Dr. Roy’s background is unique to the financial pharmaceutical sector; it combines a medical career, multiple years working for one of the leading global pharma firms, and over a decade of experience working on the sell-side, prior to launching his own independent research boutique.

Beginning his career as one of the youngest cardio-Thoracic surgeons in the U.K., Dr. Roy has “in the trenches” experience within the medical system. Working 7 years as a medical doctor provided him with a real-world understanding of how drugs are used post-trial, and how large pharmaceutical companies persuade MDs to prescribe particular drugs.

Dr. Roy then accepted a position at Roche Pharmaceuticals working in drug safety and risk assessment in the R&D division. During his 4 year period at Roche, he created and developed the firm’s risk weighted model on development pipeline and drug safety, giving him insight as to how drugs are developed and pushed through the R&D channels for the large pharma firms.

Prior to founding Foveal LLP in 2014, Dr. Roy worked on the sell-side for 10 years at Citigroup and Nomura, where he was Managing Director and head of European Healthcare Equity Research. Institutional Investor consistently lauded Dr. Roy’s analytical skills, most recently awarding him the top-ranked individual analyst 4 years in a row (health care), and ranking his team in the top-three on 3 separate occasions.